Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Aptevo Therapeutics ( (APVO) ) has provided an update.
Aptevo Therapeutics Inc. announced that it has regained compliance with Nasdaq’s listing requirements as of July 1, 2025, after previously being non-compliant due to insufficient stockholders’ equity. The company achieved compliance by raising approximately $15.9 million in additional equity capital during the quarter ended June 30, 2025, ensuring its stockholders’ equity meets the necessary threshold.
The most recent analyst rating on (APVO) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Aptevo Therapeutics stock, see the APVO Stock Forecast page.
Spark’s Take on APVO Stock
According to Spark, TipRanks’ AI Analyst, APVO is a Underperform.
Aptevo Therapeutics’ stock score is significantly impacted by its challenging financial performance, marked by declining revenues, high leverage, and negative cash flows. The technical analysis indicates bearish momentum, while the valuation is weakened by persistent losses. However, promising developments in its oncology pipeline offer potential upside if successfully executed.
To see Spark’s full report on APVO stock, click here.
More about Aptevo Therapeutics
Aptevo Therapeutics Inc. operates in the biotechnology industry, focusing on developing novel immuno-oncology and hematology therapeutics.
Average Trading Volume: 2,450,935
Technical Sentiment Signal: Strong Sell
Current Market Cap: $9.93M
See more insights into APVO stock on TipRanks’ Stock Analysis page.